Additionally, targeted therapies against specific mutations such as EGFR and ALK have shown promising efficacy [15,16] However, with the diverse molecular profiles of NSCLC and variations in treatment response, resistance, and tolerability, research continues to evaluate the efficacy of additional monotherapy and dual-therapy approaches for patients with advanced NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.